Metalloproteinases and cell fate: Notch just ADAMs anymore

Eric T. Sawey, Howard C. Crawford

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Notch signaling is involved both in development as well as in multiple cancers, including pancreatic cancer. Its activity has been implicated early in pancreatic disease, shown to be essential for a pre-cancerous transdifferentiation event known as acinar-toductal metaplasia (ADM). Recently, we have shown that matrix metalloproteinase-7 (MMP-7) is essential for ADM by activating the Notch pathway, challenging the notion that ADAM metalloproteinases are the sole enzymes responsible for initiating Notch activity. In ADM, ADAMs do not compensate for the absence of MMP-7 activity. We propose that during development and stem cell maintenance, Notch activation is highly regulated by the binding of Notch ligand to receptor and employs the ubiquitously-expressed ADAMs, whereas in a disease state, high levels of induced MMP-7 activity can lead to aberrant ligand-independent Notch activation. Therefore, if ADM or PDA is to be blocked by inhibiting Notch, treatment with ADAM-specific inhibitors alone will be inadequate. Other approaches for Notch inhibition, including by γ-secretase and broad-spectrum MMP inhibitors, will be discussed.

Original languageEnglish (US)
Pages (from-to)566-569
Number of pages4
JournalCell Cycle
Volume7
Issue number5
StatePublished - Mar 1 2008
Externally publishedYes

Fingerprint

Matrix Metalloproteinase 7
Metaplasia
Metalloproteases
Chemical activation
Ligands
Amyloid Precursor Protein Secretases
Matrix Metalloproteinase Inhibitors
Personal digital assistants
Stem cells
Pancreatic Diseases
Pancreatic Neoplasms
Stem Cells
Maintenance
Enzymes
Neoplasms

Keywords

  • ADAM-10
  • ADAM-17
  • Gamma secretase inhibitor
  • Jagged
  • Matrilysin
  • Metaplasia
  • MMP-7
  • Pancreatic cancer
  • Transdifferentiation

ASJC Scopus subject areas

  • Biochemistry
  • Cell Biology
  • Molecular Biology

Cite this

Sawey, E. T., & Crawford, H. C. (2008). Metalloproteinases and cell fate: Notch just ADAMs anymore. Cell Cycle, 7(5), 566-569.

Metalloproteinases and cell fate : Notch just ADAMs anymore. / Sawey, Eric T.; Crawford, Howard C.

In: Cell Cycle, Vol. 7, No. 5, 01.03.2008, p. 566-569.

Research output: Contribution to journalArticle

Sawey, ET & Crawford, HC 2008, 'Metalloproteinases and cell fate: Notch just ADAMs anymore', Cell Cycle, vol. 7, no. 5, pp. 566-569.
Sawey ET, Crawford HC. Metalloproteinases and cell fate: Notch just ADAMs anymore. Cell Cycle. 2008 Mar 1;7(5):566-569.
Sawey, Eric T. ; Crawford, Howard C. / Metalloproteinases and cell fate : Notch just ADAMs anymore. In: Cell Cycle. 2008 ; Vol. 7, No. 5. pp. 566-569.
@article{aa0a7622654845a3aab03c869912159b,
title = "Metalloproteinases and cell fate: Notch just ADAMs anymore",
abstract = "Notch signaling is involved both in development as well as in multiple cancers, including pancreatic cancer. Its activity has been implicated early in pancreatic disease, shown to be essential for a pre-cancerous transdifferentiation event known as acinar-toductal metaplasia (ADM). Recently, we have shown that matrix metalloproteinase-7 (MMP-7) is essential for ADM by activating the Notch pathway, challenging the notion that ADAM metalloproteinases are the sole enzymes responsible for initiating Notch activity. In ADM, ADAMs do not compensate for the absence of MMP-7 activity. We propose that during development and stem cell maintenance, Notch activation is highly regulated by the binding of Notch ligand to receptor and employs the ubiquitously-expressed ADAMs, whereas in a disease state, high levels of induced MMP-7 activity can lead to aberrant ligand-independent Notch activation. Therefore, if ADM or PDA is to be blocked by inhibiting Notch, treatment with ADAM-specific inhibitors alone will be inadequate. Other approaches for Notch inhibition, including by γ-secretase and broad-spectrum MMP inhibitors, will be discussed.",
keywords = "ADAM-10, ADAM-17, Gamma secretase inhibitor, Jagged, Matrilysin, Metaplasia, MMP-7, Pancreatic cancer, Transdifferentiation",
author = "Sawey, {Eric T.} and Crawford, {Howard C.}",
year = "2008",
month = "3",
day = "1",
language = "English (US)",
volume = "7",
pages = "566--569",
journal = "Cell Cycle",
issn = "1538-4101",
publisher = "Landes Bioscience",
number = "5",

}

TY - JOUR

T1 - Metalloproteinases and cell fate

T2 - Notch just ADAMs anymore

AU - Sawey, Eric T.

AU - Crawford, Howard C.

PY - 2008/3/1

Y1 - 2008/3/1

N2 - Notch signaling is involved both in development as well as in multiple cancers, including pancreatic cancer. Its activity has been implicated early in pancreatic disease, shown to be essential for a pre-cancerous transdifferentiation event known as acinar-toductal metaplasia (ADM). Recently, we have shown that matrix metalloproteinase-7 (MMP-7) is essential for ADM by activating the Notch pathway, challenging the notion that ADAM metalloproteinases are the sole enzymes responsible for initiating Notch activity. In ADM, ADAMs do not compensate for the absence of MMP-7 activity. We propose that during development and stem cell maintenance, Notch activation is highly regulated by the binding of Notch ligand to receptor and employs the ubiquitously-expressed ADAMs, whereas in a disease state, high levels of induced MMP-7 activity can lead to aberrant ligand-independent Notch activation. Therefore, if ADM or PDA is to be blocked by inhibiting Notch, treatment with ADAM-specific inhibitors alone will be inadequate. Other approaches for Notch inhibition, including by γ-secretase and broad-spectrum MMP inhibitors, will be discussed.

AB - Notch signaling is involved both in development as well as in multiple cancers, including pancreatic cancer. Its activity has been implicated early in pancreatic disease, shown to be essential for a pre-cancerous transdifferentiation event known as acinar-toductal metaplasia (ADM). Recently, we have shown that matrix metalloproteinase-7 (MMP-7) is essential for ADM by activating the Notch pathway, challenging the notion that ADAM metalloproteinases are the sole enzymes responsible for initiating Notch activity. In ADM, ADAMs do not compensate for the absence of MMP-7 activity. We propose that during development and stem cell maintenance, Notch activation is highly regulated by the binding of Notch ligand to receptor and employs the ubiquitously-expressed ADAMs, whereas in a disease state, high levels of induced MMP-7 activity can lead to aberrant ligand-independent Notch activation. Therefore, if ADM or PDA is to be blocked by inhibiting Notch, treatment with ADAM-specific inhibitors alone will be inadequate. Other approaches for Notch inhibition, including by γ-secretase and broad-spectrum MMP inhibitors, will be discussed.

KW - ADAM-10

KW - ADAM-17

KW - Gamma secretase inhibitor

KW - Jagged

KW - Matrilysin

KW - Metaplasia

KW - MMP-7

KW - Pancreatic cancer

KW - Transdifferentiation

UR - http://www.scopus.com/inward/record.url?scp=41849143767&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41849143767&partnerID=8YFLogxK

M3 - Article

C2 - 18239463

AN - SCOPUS:41849143767

VL - 7

SP - 566

EP - 569

JO - Cell Cycle

JF - Cell Cycle

SN - 1538-4101

IS - 5

ER -